only evidence-based resource combining gastroenterology and hepatology, this
major textbook critically appraises the evidence for diagnosis, screening, and
treatment of gastrointestinal and hepatic diseases, and provides clear recommendations
A unique feature is the grading of both the evidence (randomized controlled trials, systematic reviews, or lower quality trials) and the treatment recommendations. This structure provides the reader with valuable guidance on implementation.
The third edition has been fully revised, providing the latest reviews of the evidence. It is also enhanced with new topics that have significant evidence for treatment, including;
- Esinophilic esophagitis
- Acute dysenteries
- Prevention and treatment of travellers’ diarrhoea
- Frequency of adverse drug effects on bowel function
- Management of hepatitis B
- Management of Hepatitis C
- Vascular disorder of the liver
- Non invasive diagnosis of liver fibrosis
- Drug induced liver disease
Table of Contents
- 1 Introduction (John WD. McDonald, Brian G. Feagan and Andrew K. Burroughs)
Part I: Gastrointestinal disorders
- 2 Gastroesophageal reflux disease (Naoki Chiba and Brian M. Fennerty).
- 3 Barrett’s esophagus, (Constantine A Soulellis, Marc Bradette, Naoki Chiba, M. Brian Fennerty and Carlo A Fallone).
- 4 Esophageal motility disorders: achalasia and spastic motor disorders, (Jason R. Roberts, Marcelo F. Vela and Joel E Richter).
- 5 Eosinophilic esophagitis, (Elizabeth J. Elliott).
- 6 Ulcer disease and Helicobacter pylori infection: etiology and treatment, (Naoki Chiba).
- 7 Non-steroidal, anti-inflammatory, drug-induced, gastro-duodenal toxicity, (Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Peter Tugwell and George Wells).
- 8 Acute non-variceal gastrointestinal hemorrhage: treatment, (Nicholas Church and Kelvin Palmer)
- 9 Functional dyspepsia (Sander Veldhuyzen van Zanten)
- 10 Celiac disease: diagnosis, treatment and prognosis, (James Gregor and Michael Sai Lai Sey).
- 11 Crohn’s disease, (Brian G. Feagan and John WD. McDonald).
- 12 Ulcerative colitis, (Derek P. Jewell, Lloyd R Sutherland, John WD. McDonald and Brian G. Feagan).
- 13 Pouchitis after restorative proctocolectomy, (Darrell S. Pardi and William J. Sandborn).
- 14 Microscopic colitis: collagenous and lymphocytic colitis, (Johan Bohr, Robert Löfberg and Curt Tysk).
- 15 Drug-induced diarrhea, Bincy P. Abraham and Joseph H. Sellin).
- 16 Metabolic bone disease in gastrointestinal disorders, (Ann Cranney, Alaa Rostom, Catherine Dubé, Rachid Mohamed, Peter Tugwell, George Wells and John MacDonald).
- 17 Colorectal cancer in ulcerative colitis: surveillance,(Paul Collins, Bret A. Lashner and Alastair JM Watson).
- 18 Colorectal cancer: population screening and surveillance, (Theodore R. Levin and Linda Rabeneck).
- 19 Prevention and treatment of travelers’ diarrhea, (Herbert L DuPont).
- 20 Clostridium difficile associated disease: diagnosis and treatment, (Lynne V McFarland and Christina M Surawicz).
- 21 Irritable bowel syndrome, (Alexander C. Ford, Paul Moayyedi and Nicholas J. Talley).
- 22 Ogilvie’s syndrome, (Michael D. Saunders).
- 23 Gallstone disease, (Laura VanderBeek, Calvin HL Law and Véd R Tandan).
- 24 Acute pancreatitis, (Colin D. Johnson and Hassan Elberm).
- 25 Obesity management: considerations for the gastroenterologist, (Leah Gramlich, Marilyn Zeman and Arya M Sharma).
Part II: Liver disease
- 26 Hepatitis C, (Keyur Patel, Hans Tillmann and John G. McHutchison).
- 27 Hepatitis B: prognosis and treatment, (Piero Almasio, Calogero Cammà, Vito Di Marco and Antonia Craxì).
- 28 Alcoholic liver disease, (Hélène Castel and Philippe Mathurin).
- 29 Non-alcoholic fatty liver disease, (Christopher P. Day).
- 30 Hemochromatosis, (Gary P. Jeffrey, Paul C. Adams).
- 31 Wilson’s disease, (James S. Dooley and Aftab Ala).
- 32 Primary biliary cirrhosis, (Gideon M. Hirschfield and E. Jenny Heathcote).
- 33 Autoimmune hepatitis, (Michael MP. Manns and Arndt Vogel).
- 34 Primary sclerosing cholangitis, (Nishchay Chandra, Susan N. Cullen and Roger W. Chapman).
- 35 Non-histological assessment of liver fibrosis, (Dominique Thabut, Marika Simon-Rudler).
- 36 Portal hypertensive bleeding, (Christos Triantos, John Goulis, Andrew K. Burroughs).
- 37 Hepatic outflow syndromes and splanchnic venous thrombosis, (Marco Senzolo, Neeral Shah, David Patch and Stephen Caldwell).
- 38 Ascites, hepatorenal syndrome and spontaneous bacterial peritonitis, (Pere Ginès, Andrés Cárdenas, Vicente Arroyo and Juan Rodés).
- 39 Hepatic encephalopathy: treatment, (Peter Ferenci and Christian Müller).
- 40 Hepatocellular carcinoma (Massimo Colombo and Massimo Iavarone).
- 41 Fulminant hepatic failure: treatment, (James O’Beirne, Nick Murphy and Julia Wendon).
- 42 Liver transplantation: prevention and treatment of rejection, (Maria Pleguezuelo, Giacomo Germani and Andrew K. Burroughs).
- 43 Liver transplantation: prevention and treatment of nfection, (Antoni Rimola and Miquel Navasa).
- 44 Management of HCV infection and liver transplantation, (Brett E. Fortune, Hugo R. Rosen and James R. Burton, Jr).
- 45 Management of HBV infection and liver transplantation, (Evangelos Cholongitas and George V. Papatheodoridis).
- 46 Liver biopsy, (Evangelos Cholongitas, Andrew K. Burroughs and Amar P. Dhillon).
- 47 Drug induced liver disease: mechanisms and diagnosis, (Raúl J Andrade and Isabel Lucena).
John McDonald, Professor of Gastroenterology at the University of Ontario, London Ontario, Coordinating Editor in the Cochrane Collaboration Steering Committee on methodology, and Past President of the Canadian College of Gastroenterology
Professor Andrew Burroughs MBChB Hons FRCP
Consultant Physician and Hepatologist, Royal Free Hospital, London, has an international reputation as a clinical and academic Hepatologist and has published widely in all areas of liver disease. He is a full time clinician and has been awarded a personal chair, as Professor of Hepatology in the University of London.
Brian Feagan is Professor of Medicine and Epidemiology and Biostatistics at the University of Western Ontario. He holds cross-appointments in the Divisions of Internal Medicine, Clinical Pharmacology and Gastroenterology. He is a specialist in Internal Medicine with training in Clinical Epidemiology and Gastroenterology who has been the lead investigator in the design and implementation of randomized controlled trials since 1986. In addition to being an internationally recognized expert in the therapy of Inflammatory Bowel Disease, Dr. Feagan has conducted trials on behalf of Industry and peer-reviewed agencies in a wide range of disease states. Dr. Feagan is interested in the evaluation of Health Related Quality of Life (HRQL) and has performed research on the operating properties of HRQL instruments.